- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03675113
Effect of Upper Extremity Aerobic Exercise Training on Exercise Capacity Patients With Chronic Heart Failure
October 20, 2020 updated by: Meral Boşnak Güçlü, Gazi University
Effects of Upper Extremity Aerobic Exercise Training on Exercise Capacity and Physical Activity Level in Patients With Chronic Heart Failure
Heart failure is a cardiac structural or functional disorder that, despite normal filling pressures, leads to inability to deliver enough oxygen to meet the metabolic needs o tissue.
Heart failure is a serious chronic condition that affects a large proportion of the adult population in the world causing high mortality, leading to exercise intolerance and reduced health-related quality of life.
Patients included in the cardiac rehabilitation program slow down disease progression, hospitalization decreases, quality of life improves and health expenditures decrease.
Despite the frequent use of upper extremities in daily living activities, studies investigating the effect of upper extremity aerobic training on daily living activities, functional exercise capacity and other outcomes are limited.
No studies have investigated the effect of upper extremity aerobic exercise training on physical activity level, functional and maximal exercise capacity and other measures in patients with heart failure.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
It has been reported that exercise capacity in peak arm exercise is almost 30% lower in heart failure patients.
For this reason intolerance to arm exercise is a significant problem in heart failure patients and may contribute to a decrease in performance in activities of daily living.
Considering the fact that developments in these patients are caused by vasculature functional adaptation the extremity skeletal muscle and applied limbs, upper extremity exercises may be useful to reduce exercise intolerance during activities requiring continuous arm movement.
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ankara, Turkey, 06500
- Gazi University Faculty of Health Science Department of Physiotherapy and Rehabilitation
-
-
Yenimahalle
-
Ankara, Yenimahalle, Turkey, 06500
- Gazi University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with a diagnosis of chronic heart failure diagnosed at rest below 40% of the left ventricular ejection fraction and class 1-3 according to the New York Heart Association classification
- Optimal medical treatment at least 30 days and clinically stable
Exclusion Criteria:
- Patients with unstable angina pectoris
- Decompensated heart failure
- Primary pulmonary hypertension
- Complex ventricular arrhythmia
- Contraindication to cardiopulmonary exercise testing
- Patients who have had myocardial ischemia in the past 3 months
- Ischemic cerebrovascular events
- Second and third degree atrioventricular block
- Thrombus detected in the left ventricle
- Uncontrolled insulin dependent diabetes mellitus
- Uncontrolled hypertension
- Renal insufficiency
- Acute infection
- Aortic stenosis
- Acute pulmonary embolism
- Mental, musculoskeletal, neurological, or systemic illness that will prevent exercise.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: upper extremity aerobic group
The upper extremity aerobic exercise training with an arm ergometer will be performed in the treatment group so that training intensity will be between 60% and 80% of the maximum heart rate, dyspnea perception will be 3-4 according to Modified Borg Scale and fatigue perception will be 5-6 according to Modified Borg Scale, training duration will be 3 day per a week through 6-weeks.
|
Range of maximal heart rate will be followed by a polar band during supervised session each week. Aerobic exercise will be trained for 30 min-per/day, 3 days/week, 6 weeks. All sessions are being performed by a physiotherapist at cardiopulmonary rehabilitation department. |
Sham Comparator: control group
Deep breathing exercises combination with arm movements will be given as a home program in the control group.
Training duration will be 3 day per a week through 6-weeks.
|
Deep breathing exercises combinated with arm movements
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximal exercise capacity
Time Frame: Second day
|
It will be evaluated using symptom limited cardiopulmonary exercise testing.
The cardiopulmonary exercise test will be performed at a progressively increasing speed and grade
|
Second day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pulmonary function
Time Frame: First day
|
Dynamic lung volume measurements will be performed using a spirometry according to the American Thoracic Society and European Respiratory Society criteria.
|
First day
|
Respiratory muscle strength
Time Frame: First day
|
Maximal inspiratory and expiratory muscle strength will be evaluated a using mouth pressure device.
|
First day
|
Pulmonary muscle endurance
Time Frame: First day
|
It will be evaluated incremental threshold loading test, in which participants started an initial load of 30% of maximal inspiratory pressure with a 10% increment every 2 minutes.
|
First day
|
Peripheral muscle strength
Time Frame: First day
|
It will be evaluated using a portable hand held Dynamometer.
|
First day
|
Grip strength
Time Frame: First day
|
It will be evaluated using a grip dynamometer.
|
First day
|
Functional impairment due to dyspnea
Time Frame: First day
|
It will be evaluated with modified Medical Research Council Dyspnea Scale (MMRC).
MMRC is a baseline assessment of functional impairment attributable to dyspnea from respiratory disease.
modified Medical Research Council (mMRC) Dyspnea Scale, which consist of five-item scale based on a variety of physical activities that cause a feeling of dyspnea, was used to determine the severity of patients' shortness of breath.
The participants read and chose the most appropriate scale option between 0 and 4 that best describes the degree of their pulmonary distress.
|
First day
|
Physical activity level
Time Frame: First day
|
Physical activity will be evaluated multi sensor activity monitor for 4 consecutive days.
|
First day
|
Functional exercise capacity
Time Frame: First day
|
Six minute pegboard and ring test (6-PBRT) was applied to assess the functional capacity of the upper limbs.
Subjects are asked to move as many rings as possible in 6 minutes, and the score is the number of rings moved during the 6-minute period.
|
First day
|
Activity daily of living
Time Frame: Second day
|
London Chest Activity Daily of Living Scale is a 15-item scale divided into 4 domains: self-care (4 items), domestic (6 items), physical (2 items), and leisure (3 items).The total score is calculated by summing the domains and ranges from 0 to 75, with higher values indicating more marked limitation in activity daily of living performance.
|
Second day
|
Quality of sleep
Time Frame: Second day
|
Pittsburgh Sleep Quality Index (Turkish version) (PSQI) is a self-reported questionnaire.
PSQI evaluates patients' sleep quality.
The scale includes 24 questions overall, with 19 questions answered by the person him/ herself and the remaining 5 answered by his/her bed partner or roommate.
The first 19 self-answered questions evaluate 7 subscales, subjective sleep quality, sleep latency, duration of sleep, routine sleep activity, sleep disorders, the use of drugs for sleeping, and daytime dysfunction.
Each item in the scale is scored between 0 and 3 (no difficulty to severe difficulty).
The sum of the 7 subscale scores gives the overall PSQI score.
Lower scores show better sleep quality.
|
Second day
|
Fatigue
Time Frame: Second day
|
Fatigue Severity Scale (Turkish version) - Fatigue Severity Scale (FSS) is a self-reported questionnaire.
FSS evaluates patient's fatigue severity.
This questionnaire includes 9 items and score range for each item from 1 to 7 point (7-point Likert scale).
Fatigue Severity Scale score is calculates by deriving an arithmetic mean.
Cut-scores of over 4 are indicative of significant fatigue (higher scores show more severe fatigue).
|
Second day
|
Anxiety and depression
Time Frame: Second day
|
Hospital Anxiety and Depression (Turkish version).
The test used to determine the risk group of patients in terms of anxiety and depression and consists of 14 questions.
Lowest score that patients can get from both subscales is 0, the highest score 21.
The cut-off points for the Turkish version of the HAD scale were 10 for the anxiety subscale (HAD-A) and 7 for the depression subscale (HAD-D).
|
Second day
|
Quality of life scale
Time Frame: Second day
|
Minnesota Living with Heart Failure Questionnaire (MLHFQ) (Turkish version of scale) 21 items rated on six-point Likert scales, representing different degrees of impact of heart failure on Heart Related Quality of Life (HRQoL), from 0 (none) to 5 (very much).
It provides a total score (range 0-105, from best to worst HRQoL), as well as scores for two dimensions, physical (8 items, range 0-40) and emotional (5 items, range 0-25).
|
Second day
|
Dyspnea
Time Frame: Second day
|
It will be evaluated modified Borg Scale.
This modified 12-point scale consists (0, 0.5, 1-10) corresponds with increasing shortness of breath.
Patients were asked to mark the most appropriate description or number of their shortness of breath at rest and during exercise.
|
Second day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Meral Boşnak Güçlü, PhD, Gazi University
- Study Chair: Hanım Eda GÖKTAŞ, MSc, Gazi University
- Principal Investigator: Adnan ABACI, PhD, Gazi University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Giannuzzi P, Temporelli PL, Corra U, Tavazzi L; ELVD-CHF Study Group. Antiremodeling effect of long-term exercise training in patients with stable chronic heart failure: results of the Exercise in Left Ventricular Dysfunction and Chronic Heart Failure (ELVD-CHF) Trial. Circulation. 2003 Aug 5;108(5):554-9. doi: 10.1161/01.CIR.0000081780.38477.FA. Epub 2003 Jul 14.
- Ades PA, Keteyian SJ, Balady GJ, Houston-Miller N, Kitzman DW, Mancini DM, Rich MW. Cardiac rehabilitation exercise and self-care for chronic heart failure. JACC Heart Fail. 2013 Dec;1(6):540-7. doi: 10.1016/j.jchf.2013.09.002. Epub 2013 Oct 24.
- Antunes-Correa LM, Kanamura BY, Melo RC, Nobre TS, Ueno LM, Franco FG, Roveda F, Braga AM, Rondon MU, Brum PC, Barretto AC, Middlekauff HR, Negrao CE. Exercise training improves neurovascular control and functional capacity in heart failure patients regardless of age. Eur J Prev Cardiol. 2012 Aug;19(4):822-9. doi: 10.1177/1741826711414626. Epub 2011 Jun 22.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 5, 2018
Primary Completion (Anticipated)
June 1, 2020
Study Completion (Anticipated)
December 1, 2020
Study Registration Dates
First Submitted
September 12, 2018
First Submitted That Met QC Criteria
September 14, 2018
First Posted (Actual)
September 18, 2018
Study Record Updates
Last Update Posted (Actual)
October 22, 2020
Last Update Submitted That Met QC Criteria
October 20, 2020
Last Verified
October 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Gazi University 14
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Heart Failure
-
Maastricht University Medical CenterUniversity College Dublin; RWTH Aachen University; Queen's University, BelfastCompletedChronic Heart FailureNetherlands, Germany, Ireland, United Kingdom
-
Wuerzburg University HospitalRecruitingHeart Failure | Chronic Heart Failure | Chronic Heart DiseaseGermany
-
Jordan Cardio Vascular Research GroupRecruitingHeart Failure | Chronic Heart Failure | Acute Heart FailureJordan
-
Lithuanian University of Health SciencesCompletedHeart Failure | Chronic Heart Failure | Congestive Heart Failure | Right Ventricular FailureLithuania
-
Zensun Sci. & Tech. Co., Ltd.RecruitingChronic Heart FailureChina
-
University Hospital, Clermont-FerrandHospices Civils de Lyon; University Hospital, Grenoble; Hôpital de la Croix-Rousse and other collaboratorsRecruitingHeart Failure | Chronic Heart Failure | Acute Heart FailureFrance
-
University of Roma La SapienzaUnknownChronic Heart Failure | Decompensated Heart Failure | Morality
-
University Medicine GreifswaldDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)RecruitingChronic Heart FailureGermany
-
AquaPass Medical Ltd.CompletedChronic Heart FailureIsrael
-
Zensun Sci. & Tech. Co., Ltd.Terminated
Clinical Trials on Upper extremity aerobic exercise
-
Gazi UniversityCompletedHematopoietic Stem Cell Transplantation | Aerobic ExerciseTurkey
-
Gazi UniversityCompleted
-
Gazi UniversityNot yet recruiting
-
The Cleveland ClinicActive, not recruitingCardiovascular Diseases | Vascular Diseases | Stroke | Cerebrovascular Disorders | Brain Diseases | Central Nervous System Diseases | Nervous System DiseasesUnited States
-
Gazi UniversityRecruitingPrimary ImmunodeficiencyTurkey
-
Riphah International UniversityRecruiting
-
National and Kapodistrian University of AthensNot yet recruiting
-
Gazi UniversityRecruitingInterstitial Lung DiseaseTurkey
-
US Department of Veterans AffairsCompleted
-
The Cleveland ClinicAmerican Heart AssociationCompleted